FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer
The Food and Drug administration (FDA) in the USA has [...]
International Kidney Cancer Symposium (IKCS) 2021
The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]
Risks and benefits of adjuvant therapy for kidney cancer
Treatment of people with intermediate to high risk renal cell [...]
ESMO 2021: Pembrolizumab as adjuvant therapy
Adjuvant therapy is medication that is given in addition to [...]
ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer
Adjuvant therapy is medication that is given in addition to [...]
Adjuvant pembrolizumab extends disease-free survival in kidney cancer patients
Interim results from a phase 3 clinical trial called KEYNOTE-564 [...]
IKCS 2020: Treatment selection in kidney cancer
During this interview, Dr Rana McKay from the University of [...]
Stereotactic radiation for the treatment of kidney cancer
This paper reviews the use of stereotactic body radiotherapy (SBRT) [...]
ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib
Results from the SORCE clinical trial to assess sorfenib as [...]
ASCO 2019: Effectiveness of pazopanib after kidney cancer metastasectomy
In this phase III study, presented at the American Society [...]
